Zacks Investment Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.65M Buy
62,229
+8,935
+17% +$375K 0.03% 293
2026
Q1
$1.72M Sell
53,294
-2,842
-5% -$105K 0.01% 365
2025
Q4
$2.36M Buy
56,136
+3,855
+7% +$155K 0.02% 324
2025
Q3
$1.79M Buy
52,281
+3,595
+7% +$103K 0.01% 345
2025
Q2
$1.32M Sell
48,686
-1,580
-3% -$45.8K 0.01% 370
2025
Q1
$1.49M Buy
50,266
+668
+1% +$25.5K 0.01% 363
2024
Q4
$1.96M Buy
49,598
+16,603
+50% +$629K 0.02% 341
2024
Q3
$1.12M Buy
+32,995
New +$928K 0.01% 394

Other funds holding VCYT

Zacks Investment Management's VCYT Position: Q2 2026 in Review

Zacks Investment Management increased its Veracyte (VCYT) stake by 17% in Q2 2026, buying an estimated $375K and bringing the position to 62,229 shares worth $3.65M. The position accounts for 0.03% of the portfolio, ranked #293.

Zacks Investment Management first reported a position in VCYT in Q3 2024 and has held it in 8 quarters since. 370 funds tracked by Wall St. Rank hold VCYT as of Q2 2026.

  • Zacks Investment Management held 62,229 shares of Veracyte worth $3.65M as of Q2 2026.
  • Zacks Investment Management bought 8,935 Veracyte shares in Q2 2026, an estimated $375K.
  • Veracyte made up 0.03% of Zacks Investment Management's portfolio in Q2 2026, its #293 holding.
  • Zacks Investment Management first reported a position in Veracyte in Q3 2024 and has held it in 8 quarters since.
  • 370 funds tracked by Wall St. Rank held Veracyte as of Q2 2026.

Based on Zacks Investment Management's 13F filing for Q2 2026, filed 13 Aug 2026.